Evaluation of treatment regimens to cure Helicobacter pylori infection—a meta-analysis
Article first published online: 24 DEC 2001
Alimentary Pharmacology & Therapeutics
Volume 13, Issue 7, pages 857–864, July 1999
How to Cite
Laheij, Rossum, L. G. M. V., Jansen, Straatman and Verbeek (1999), Evaluation of treatment regimens to cure Helicobacter pylori infection—a meta-analysis . Alimentary Pharmacology & Therapeutics, 13: 857–864. doi: 10.1046/j.1365-2036.1999.00542.x
- Issue published online: 24 DEC 2001
- Article first published online: 24 DEC 2001
: To assess effectiveness of treatment to cure Helicobacter pylori infection.
: Meta-analysis of 666 manuscripts (full papers, abstracts, letters to the editor) identified through Medline and a manual search (1986 to January 1998). Data were overviewed by regression analysis with weighted random effects models.
: 53 228 patients with H. pylori infection.
: Patients were treated with 132 different medication combinations.
Main outcome measure
: Cure of H. pylori infection per protocol and intention-to-treat basis at least 28 days after treatment.
The nationality of the patients and therapeutic regimen have a significant impact on the results, after correction for the heterogeneity in the precision of the cure rate caused by different study sizes and random effect for study. On the basis of the original sample size, cure rates of 80–85% were achieved using combinations of a proton-pump inhibitor or ranitidine bismuth citrate with two antibiotics including clarithromycin, amoxycillin and metronidazole or tinidazole. Comparable cure rates were also achieved using a combination of a proton-pump inhibitor or H2-receptor antagonist with bismuth subcitrate or tripotassium dicitrato bismuthate, metronidazole and tetracycline. The dose of clarithromycin influenced cure rates. Treatment duration did not influence the outcome.
Several therapeutic regimens are eligible to cure H. pylori infection. However, none of the medication combinations were able to cure H. pylori infection in more than 85% of the patients assessed by intention-to-treat. The countries in which the studies were performed also had a significant impact on eradication rates.